Design, Synthesis, and in Vitro Biological Evaluation of Small Molecule Inhibitors of Estrogen Receptor α Coactivator Binding

Journal of Medicinal Chemistry

Volumn 47, Issue 3, 2004, Pages 600-611

  Rodriguez, Alice L ^a   Tamrazi, Anobel ^a   Collins, Margaret L ^a   Katzenellenbogen, John A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYL GROUP; AMINE; COACTIVATOR BINDING INHIBITOR; CYCLOHEXANE; ESTROGEN RECEPTOR AGONIST; ESTROGEN RECEPTOR ALPHA; HETEROCYCLIC COMPOUND; LEUCINE; LIGAND; NAPHTHALENE; PEPTIDE; PYRIMIDINE DERIVATIVE; TRIAZENE DERIVATIVE; UNCLASSIFIED DRUG;

AGONIST; ANISOTROPY; ARTICLE; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG DESIGN; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE ANALYSIS; HYDROPHOBICITY; LIGAND BINDING; PROTEIN DOMAIN; PROTEIN MOTIF; REACTION OPTIMIZATION; STRUCTURE ANALYSIS; TRANSCRIPTION REGULATION;

AMINO ACID MOTIFS; BINDING SITES; BINDING, COMPETITIVE; CRYSTALLOGRAPHY, X-RAY; CYCLOHEXANES; DRUG DESIGN; ESTROGEN RECEPTOR ALPHA; FLUORESCENCE POLARIZATION; LIGANDS; MODELS, MOLECULAR; MOLECULAR MIMICRY; MOLECULAR STRUCTURE; NAPHTHALENES; PEPTIDES; PYRIMIDINES; RECEPTORS, ESTROGEN; TRIAZENES;

EID: 1642581072     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030404c     Document Type: Article

References (48)

1. McKenna, N. J.; O'Malley, B. W. Minireview: Nuclear receptor coactivators-an update. Endocrinology 2002, 143, 2461-2465.
2. McKenna, N. J.; O'Malley, B. W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002, 108, 465-474.
3. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95, 927-937.
4. Shiau, A. K.; Barstad, D.; Radek, J. T.; Meyers, M. J.; Nettles, K. W.; et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Biol. 2002, 9, 359-364.
5. Darimont, B. D.; Wagner, R. L.; Apriletti, J. W.; Stallcup, M. R.; Kushner, P. J.; et al. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 1998, 12, 3343-3356.
6. Gampe, R. T.; Montana, V. G.; Lambert, M. H.; Miller, A. B.; Bledsoe, R. K.; et al. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 2000, 5, 545-555.
7. Egea, P. F.; Mitschler, A.; Moras, D. Molecular recognition of agonist ligands by RXRs. Mol. Endo. 2002, 16, 987-997.
8. Warnmark, A.; Treuter, E.; Gustafsson, J.; Hubbard, R. E.; Brzozowski, A. M.; et al. Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha. J. Biol. Chem. 2002, 277, 21862-21868.
9. Xu, H. E.; Stanley, T. B.; Montana, V. G.; Lambert, M. H.; Shearer, B. G.; et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR alpha. Nature 2002, 415, 813-817.
10. Mi, L. Z.; Devarakonda, S.; Harp, J. M.; Han, Q.; Pellicciari, R.; et al. Structural Basis for Bile Acid Binding and Activation of the Nuclear Receptor FXR. Mol. Cell 2003, 11, 1093-1100.
11. Downes, M.; Verdecia, M. A.; Roecker, A. J.; Hughes, R.; Hogenesch, J. B.; et al. A Chemical, Genetic, and Structural Analysis of the Nuclear Bile Acid Receptor FXR. Mol. Cell 2003, 11, 1079-1092.
12. Brzozowski, A. M.; Pike, A. C.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, 753-758.
13. Pike, A. C.; Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.; Thorsell, A. G.; et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999, 18, 4608-4618.
14. Pike, A. C.; Brzozowski, A. M.; Walton, J.; Hubbard, R. E.; Thorsell, A. G.; et al. Structural insights into the mode of action of a pure antiestrogen. Structure (Camb) 2001, 9, 145-153.
15. Shang, Y.; Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 2002, 295, 2465-2468.
16. Schiff, R.; Massarweh, S.; Shou, J.; Osborne, C. K. Breast cancer endocrine resistance: How growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res. 2003, 9, 447S-454S.
17. Osborne, C. K.; Bardou, V.; Hopp, T. A.; Chamness, G. C.; Hilsenbeck, S. G.; et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 2003, 95, 353-361.
18. Norris, J. D.; Paige, L. A.; Christensen, D. J.; Chang, C. Y.; Huacani, M. R.; et al. Peptide antagonists of the human estrogen receptor. Science 1999, 285, 744-746.
19. Connor, C. E.; Norris, J. D.; Broadwater, G.; Willson, T. M.; Gottardis, M. M.; et al. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res 2001, 61, 2917-2922.
20. Pope, A. J.; Haupt, U. M.; Moore, K. J. Homogeneous fluorescence readouts for miniaturized high-throughput screening: Theory and practice. Drug Discov. Today 1999, 4, 350-362.
21. Jameson, D. M.; Seifried, S. E. Quantification of protein-protein interactions using fluorescence polarization. Methods 1999, 19, 222-233.
22. Gee, A. C.; Carlson, K. E.; Martini, P. G. V.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Mol. Endocrinol. 1999, 13, 1912-1923.
23. Tamrazi, A.; Carlson, K. E.; Daniels, J. R.; Hurth, K. M.; Katzenellenbogen, J. A. Estrogen receptor dimerization: Ligand binding regulates dimer affinity and dimer dissociation rate. Mol. Endocrinol. 2002, 16, 2706-2719.
24. Paige, L. A.; Christensen, D. J.; Gron, H.; Norris, J. D.; Gottlin, E. B.; et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 3999-4004.
25. Chang, C.; Norris, J. D.; Gron, H.; Paige, L. A.; Hamilton, P. T.; et al. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: Discovery of peptide antagonists of estrogen receptors alpha and beta. Mol. Cell Biol. 1999, 19, 8226-8239.
26. Hall, J. M.; Chang, C. Y.; McDonnell, D. P. Development of peptide antagonists that target estrogen receptor beta-coactivator interactions. Mol Endocrinol 2000, 14, 2010-2023.
27. Huang, H.-J.; Norris, J. D.; McDonnell, D. P. Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. Mol. Endocrinol. 2002, 16, 1778-1792.
28. McInerney, E. M.; Rose, D. W.; Flynn, S. E.; Westin, S.; Mullen, T. M.; et al. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev. 1998, 12, 3357-3368.
29. Geistlinger, T. R.; Guy, R. K. An inhibitor of the interaction of thyroid hormone receptor beta and glucocorticoid interacting protein 1. J. Am. Chem. Soc. 2001, 123, 1525-1526.
30. Geistlinger, T. R.; Guy, R. K. Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2. J. Am. Chem. Soc. 2003, 125, 6852-6853.
31. Leduc, A. M.; Trent, J. O.; Wittliff, J. L.; Bramlett, K. S.; Briggs, S. L.; et al. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 11273-11278.
32. Toogood, P. T. Inhibition of protein-protein association by small molecules: Approaches and progress. J. Med. Chem. 2002, 45, 1543-1558.
33. Peczuh, M. W.; Hamilton, A. D. Peptide and protein recognition by designed molecules. Chem. Rev. 2000, 100, 2479-2494.
34. Ernst, J. T.; Kutzki, O.; Debnath, A. K.; Jiang, S.; Lu, H.; et al. Design of a protein surface antagonist based on alpha-helix mimicry: Inhibition of gp41 assembly and viral fusion. Angew. Chem. Int. Ed. Engl. 2002, 41, 278-281.
35. Kutzki, O.; Park, H. S.; Ernst, J. T.; Orner, B. P.; Yin, H.; et al. Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J. Am. Chem. Soc. 2002, 124, 11838-11839.
36. Orner, B. P.; Ernst, J. T.; Hamilton, A. D. Toward proteomimetics: Terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix. J. Am. Chem. Soc. 2001, 123, 5382-5383.
37. Ernst, J. T.; Becerril, J.; Park, H. S.; Yin, H.; Hamilton, A. D. Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: Antagonism of the Bak BH3/Bcl-xL complex. Angew. Chem. Int. Ed. Engl. 2003, 42, 535-539.
38. Wang, J. L.; Liu, D.; Zhang, Z. J.; Shan, S.; Han, X.; et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 7124-7129.
39. Liu, D.; Huang, Z. Synthetic peptides and nonpeptidic molecules as probes of structure and function of Bcl-2 family proteins and modulators of apoptosis. Apoptosis 2001, 6, 453-462.
40. Huang, Z. The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules. Chem. Biol. 2002, 9, 1059-1072.
41. Huang, Z. Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis. Pharmacol. Ther. 2000, 86, 201-215.
42. Asada, S.; Choi, Y.; Uesugi, M. A Gene-Expression Inhibitor that Targets an alpha-Helix-Mediated Protein Interaction. J. Am. Chem. Soc. 2003, 125, 4992-4993.
43. Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Safe and convenient procedure for solvent purification. Organometallics 1996, 15, 1518-1520.
44. Suffert, J. Simple direct titration of organolithium reagents using N-pivaloyl-o-toluidine and/or N-pivalolyl-o-benzylaniline. J. Org. Chem. 1989, 54, 509-510.
45. Katzenellenbogen, J. A.; Johnson, H. J., Jr.; Myers, H. N. Photoaffinity labels for estrogen binding proteins of rat uterus. Biochemistry 1973, 12, 4085-4092.
46. Carlson, K. E.; Choi, I.; Gee, A.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: Evidence that an open pocket conformation is required for ligand interaction. Biochemistry 1997, 36, 14897-14905.
47. Shigehiro, O.; Tsumomu, S. N,N′,N″-Tribenzylmelamine (Patent written in Japanese). Jpn. Tokkyo Koho 1972, Patent No. JP47021109; Kind B4; Date 19720614; Application No. JP1969-45379; Application Date 19690611.
48. Stauffer, S. R.; Coletta, C. J.; Tedesco, R.; Sun, J.; Katzenellenbogen, B. S.; et al. Pyrazole Ligands: Structure-Affinity/Activity Relationships of Estrogen Receptor-a Selective Agonists. J. Med. Chem. 2000, 43, 4934-4947.